Hk inno.N Corporation (195940)

[Business Overview] HK inno.N is a leading domestic bio-healthcare company that operates an ethical pharmaceuticals (ETC) business and a Health & Beauty (H&B) business. In the ethical pharmaceuticals segment, it holds as its core product 'K-CAB,' a treatment for gastroesophageal reflux disease that is Korea's 30th new drug, and it also offers 'Rovazet,' a dyslipidemia treatment; infusion solutions; anticancer drugs (co-promotion); and 'Dapaen,' a diabetes treatment. In the H&B business, it targets general consumers through products such as the hangover-relief beverage 'Condition,' the health beverage 'Hutgaesu,' the zero-calorie iced tea 'Tea Log,' and the slow-aging skincare brand 'Be On's.' Ethical pharmaceuticals account for about 90% or more of sales, while the H&B segment accounts for about 7%. Its main customers are medical institutions such as hospitals, clinics, and pharmacies, as well as general consumers, and K-CAB holds a high share in Korea's peptic ulcer treatment market. [Competitive Strengths] HK inno.N's core competitiveness lies in the strong market position and global scalability of its innovative new drug 'K-CAB.' Based on its fast efficacy and ease of administration, K-CAB leads Korea's peptic ulcer treatment market, and with its substance patent protected through 2031, it has secured a stable period of exclusivity. In addition, having completed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and expanding royalty income in overseas markets such as China, it is demonstrating the potential to grow into a global blockbuster new drug. Its strengths also include having built a one-stop system that enhances R&D and production efficiency as a subsidiary of Kolmar Korea, and securing a stable cash cow through the No. 1 market share of its hangover-relief product 'Condition.' [Financial Performance] HK inno.N achieved sales of KRW 1.0632 trillion in 2025, growing 18.51% year on year and joining the 'KRW 1 trillion club.' Operating profit was KRW 110.9 billion in 2025, up 25.74% year on year, and the operating profit margin recorded 10.43%, showing a trend of significantly improving profitability. In particular, first-quarter 2026 sales were KRW 258.7 billion and operating profit was KRW 33.2 billion, with the operating profit margin recording 12.83%, continuing solid growth and improving profitability. This earnings growth is attributable to the strong performance of the ethical pharmaceuticals business division centered on K-CAB and the expansion of co-promotion items. [Financial Health] HK inno.N's financial health is at a sound level. As of 2025, its debt ratio was 57.85%, maintaining a stable level, and its current ratio recorded 82.07%. Its ROE (return on equity) has steadily improved from 3.28% in 2022 to 5.70% in 2025, demonstrating that capital efficiency is increasing. [Outlook] HK inno.N is expected to accelerate global growth through the U.S. market entry of its core new drug 'K-CAB' and the expansion of China royalties. In addition, in order to discover a 'post-K-CAB,' it is focusing on developing an innovative new-drug pipeline including anticancer, liver disease, autoimmune disease, and obesity treatments, thereby securing future growth drivers. The stable market share of the infusion solutions business and the possibility of improving profitability are also expected to act as positive factors.